A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor
AbstractIntroductionVarious types of skin lesions with pruritus have been reported in participants of Asian clinical trials on sodium-glucose cotransporter-2 (SGLT2) inhibitors. The aim of this study was to determine whether the diuretic effect of a SGLT2 inhibitor could modify skin hydration status in patients with type 2 diabetes mellitus.MethodsA prospective, short-term, open-label, two-parallel-arm, pilot study was conducted. Eligible patients were assigned to either a SGLT2 inhibitor (50  mg ipragliflozin once daily) group or to a dipeptidyl peptidase-4 inhibitor (50 mg sitagliptin once daily) group (control...
Source: Diabetes Therapy - October 27, 2020 Category: Endocrinology Source Type: research

Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec –Liraglutide (Ideglira)
ConclusionThe findings from this study show that in a real-world setting, the switch to IDegLira treatment is a valid option for patients who are failing to achieve glycemic control targets and/or struggling with the side effects, such as weight gain and hypoglycemia, of other insulin therapies. (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 26, 2020 Category: Endocrinology Source Type: research

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
ConclusionLobeglitazone had a tendency to improve albuminuria in patients with T2DM and had comparable effects on albuminuria as pioglitazone which has demonstrated beneficial effects.Trial RegistrationClinicalTrials.gov identifier, NCT01106131. (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 24, 2020 Category: Endocrinology Source Type: research

Psychometric Analysis Regarding the Barriers to Providing Effective Insulin Treatment in Type 2 Diabetic Patients
AbstractIntroductionA psychometric analysis on type 2 diabetic (T2D) patients was performed to assess whether glycated hemoglobin (HbA1c) levels were dependent upon either the psychologic or economic attitude toward the use of insulin as a treatment for their diabetic condition.MethodsA cross-sectional study was designed using 271 patients with T2D who regularly visited a tertiary referral hospital in South Korea from June 2019 to December 2019. Each patient enrolled in this protocol was treated with insulin for at least 6  months, had recordings of their plasma HbA1c measurement, and completed validated questionnaire...
Source: Diabetes Therapy - October 24, 2020 Category: Endocrinology Source Type: research

Insulin Pump Therapy Issues Among Adults with Type 1 Diabetes Mellitus in Saudi Arabia: A Retrospective Study
AbstractIntroductionType 1 diabetes mellitus (T1DM) is on the rise in Saudi Arabia. Management of T1DM is crucial in curbing the economic burden of this disease. Studies on insulin pump issues are scarce in the region. The present study aims to fill this gap.MethodsIn this single-centre, retrospective study done in King Abdulaziz Medical City (KAMC) from March 2018 to March 2019, a total of 118 known Saudi T1DM adults (34 males and 84 females) were included. Data on demographics, glycated haemoglobin (HbA1c) and CSII use were collected.ResultsThe most common problem encountered by the patients on CSII was breaking down of ...
Source: Diabetes Therapy - October 17, 2020 Category: Endocrinology Source Type: research

A Coloured Pen Needle Education System Improves Insulin Site Rotation Habits: Results of a Randomized Study
ConclusionThe coloured pen needles with their education materials are a novel means of encouraging injection site rotation. Community pharmacists represent an untapped resource for improving injection self-care practices. (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 16, 2020 Category: Endocrinology Source Type: research

Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring
ConclusionsTofogliflozin was more effective and safer than ipragliflozin in reducing glycemic variability and mitigating hypoglycemia risk in patients with T2DM treated with insulin glargine U300.Trial RegistrationThis trial was registered at the University Hospital Medical Information Network Clinical Trial Registry (no. UMIN000037158). (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 15, 2020 Category: Endocrinology Source Type: research

Diabetes Care During Hajj
AbstractDiabetes mellitus affects over 463 million individuals worldwide. Religious activities such as the Hajj pilgrimage have a major impact on patients with diabetes mellitus, including increasing the risk of hyperglycaemia and hypoglycaemia. This increased risk is due to dietary changes and intense physical activity during pilgrimage while being on antidiabetic medications. Approximately 20% of the pilgrims with underlying illnesses who visit Mecca are diabetic, and complications, such as diabetic ketoacidosis, nonketotic hyperosmolar state, and fatigue/unconsciousness due to hypoglycaemia, have been observed among the...
Source: Diabetes Therapy - October 15, 2020 Category: Endocrinology Source Type: research

A Response To:  Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
(Source: Diabetes Therapy)
Source: Diabetes Therapy - October 14, 2020 Category: Endocrinology Source Type: research

Sodium –Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
(Source: Diabetes Therapy)
Source: Diabetes Therapy - October 14, 2020 Category: Endocrinology Source Type: research

Association Between Fasting Blood Glucose and All-Cause Mortality in a Rural Chinese Population: 15-Year Follow-Up Cohort Study
This study included 17,902 adults from a community-based cohort study in rural China who were prospectively followed from 2003 to 2018. Generalized estimating equations were used to evaluate the association between FBG and all-cause mortality, adjusting for pertinent covariates and auto-correlations among siblings.ResultsA total of 1053 (5.9%) deaths occurred during 15  years of follow-up. There was a significant U-shaped association between all-cause mortality and FBG. Compared with the reference group (FBG of 5.6 – 
Source: Diabetes Therapy - October 11, 2020 Category: Endocrinology Source Type: research

Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type  2 Diabetes (T2DM): Rationale and Design
ConclusionThe EMPA-ICD study is the first clinical trial to assess the effect of an SGLT2 inhibitor on clinically significant ventricular arrhythmias in patients with T2DM and an ICD.Trial registrationUnique trial number, jRCTs031180120 (https://jrct.niph.go.jp/latest-detail/jRCTs031180120). (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 11, 2020 Category: Endocrinology Source Type: research

Reducing HbA1c in Type 2 Diabetes Using Digital Twin Technology-Enabled Precision Nutrition: A Retrospective Analysis
ConclusionThe results provide evidence that daily precision nutrition guidance based on CGM, food intake data, and machine learning algorithms can benefit patients with type 2 diabetes. Adherence for 3  months to the TPN Program resulted in patients achieving a 1.9 percentage point decrease in HbA1c, a 6.1% drop in weight, a 56.9% reduction in HOMA-IR, a significant decline in glucose time below range, and, in most patients, the elimination of diabetes medication use. (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 11, 2020 Category: Endocrinology Source Type: research

ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide
AbstractIntroductionDulaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), became available in Italy in April 2016. The aim of ANDREW (ActiveNotes onDulaglutide in theREalWorld), a multicenter, prospective, observational study, was to evaluate glycemic control and weight (co-primary outcomes) for up to 24  months in the real-life setting in consecutive outpatients with type 2 diabetes (T2D) who initiated dulaglutide. Co-secondary outcomes were durability of treatment effects on both glycated hemoglobin (HbA1c) and body weight.MethodsOverall, 1584 subjects (696 women, 888 men) with T2D (mean age...
Source: Diabetes Therapy - October 11, 2020 Category: Endocrinology Source Type: research

Periodontal Disease in Diabetes Mellitus: A Case –Control Study in Smokers and Non-Smokers
ConclusionSmoking damages the periodontium of even healthy individuals, but the damage is multiplied in a smoker who has DM, even though the effect of DM alone on periodontium health is relatively mild. Our results suggest a synergy between DM and smoking in terms of damage to the periodontal tissues, but the limited sample size of this study does not allow any hard conclusion to be drawn. (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 11, 2020 Category: Endocrinology Source Type: research

Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type  2 Diabetes
AbstractThe treatment aims for type  2 diabetes are to prevent complications and premature mortality, and improve quality of life. Glycaemic control is central to these aims; clinical guidelines have sought to achieve this with a stepwise approach starting with lifestyle measures and metformin, adding further medications once glycate d haemoglobin (HbA1c) levels rise above a predefined threshold. However, treatment intensification can be delayed when HbA1c levels increase, and HbA1c levels become inadequately controlled in many patients. Clinical inertia can result in sustained elevated levels of HbA1c; when combined ...
Source: Diabetes Therapy - October 11, 2020 Category: Endocrinology Source Type: research

The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review
AbstractHypoglycemia is a major barrier impeding glycemic control in persons with type 2 diabetes mellitus and creates a substantial burden on the healthcare system. Certain populations that require special attention, such as older adults and individuals with renal impairment, a longer duration of diabetes or those who have experienced prior hypoglycemia, may be at a higher risk of hypoglycemia, particularly with insulin treatment. Second-generation basal insulin analogues (insulin glargine 300 U/mL and degludec) have demonstrated reductions in hypoglycemia compared with insulin glargine 100 U/mL although evidence of this ...
Source: Diabetes Therapy - October 11, 2020 Category: Endocrinology Source Type: research

Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement
AbstractDiabetic kidney disease (DKD) occurs in approximately 20 –40% of patients with type 2 diabetes mellitus. Patients with DKD have a higher risk of cardiovascular and all-cause mortality. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and antihyperglycemic drugs form the mainstay of DKD management and aim to restrict progression to more severe stages of DKD. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) control hyperglycemia by blocking renal glucose reabsorption in addition to preventing inflammation, thereby improving endothelial function and reducing oxidative stress; consequen...
Source: Diabetes Therapy - October 5, 2020 Category: Endocrinology Source Type: research

Implementation of Empagliflozin in Patients with Diabetes Mellitus Type  2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
ConclusionEmpagliflozin treatment would reduce mortality and healthcare utilization in the patient group. The treatment strategy should be considered cost-effective, supporting a broad implementation of empagliflozin for patients with T2D and established CVD, in line with current national and international guidelines. (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 5, 2020 Category: Endocrinology Source Type: research

Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
In the original article, the Table 1 has published with error. (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 3, 2020 Category: Endocrinology Source Type: research

Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study
ConclusionIn Italian routine clinical practice, switching from other basal insulins to insulin degludec reduced the total episodes of hypoglycemia and improved glycemic control and treatment satisfaction in patients with T1DM and T2DM.Trial RegistrationClinicalTrials.gov NCT02392117. (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 2, 2020 Category: Endocrinology Source Type: research

Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLANCE Study
AbstractIntroduction Physician adherence, or lack therefore, to diabetes care and follow-up guidelines may be linked to the rates of achieving suboptimal glycaemic, blood pressure and lipid targets in people with type 2 diabetes mellitus (T2DM). In this cross-sectional study we evaluated physician adherence to the patient follow-up protocol (PFP) of the 2017 Hellenic Diabetes Association (HDA) guidelines and also assessed glycated haemoglobin (HbA1c), blood pressure and lipid control achievement rates in the routine care setting in Greece.MethodsEligible subjects were adults with T2DM receiving oral hypoglycaemic agents (O...
Source: Diabetes Therapy - October 2, 2020 Category: Endocrinology Source Type: research

Pre-Gestational Diabetes and Pregnancy Outcomes
ConclusionsWomen in our study with pre-gestational diabetes were overweight, were older and had long-standing diabetes mellitus. Our patients with type 2 diabetes had a higher BMI, were older, had a shorter duration of diabetes mellitus and had better diabetes control compared to women with type 1 diabetes. Women treated with continuous subcutaneous insulin infusion had a higher rate of miscarriage with more congenital malformations. The initial inadequate diabetes control was significantly improved during pregnancy. (Source: Diabetes Therapy)
Source: Diabetes Therapy - October 2, 2020 Category: Endocrinology Source Type: research

Does Roux-en-Y Construction Really Bring Benefit of Type  2 Diabetes Mellitus Remission After Gastrectomy in Patients with Gastric Cancer? A Systematic Review and Meta-Analysis
ConclusionTotal gastrectomy with R-Y had better T2DM remission. The extent of gastrectomy rather than the reconstruction method might play an important role in T2DM remission after gastrectomy in patients with gastric cancer. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 30, 2020 Category: Endocrinology Source Type: research

Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type  2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
AbstractIntroductionThis analysis evaluated the efficacy and safety of dulaglutide in Chinese patients with type  2 diabetes (T2D) aged ≥ 60 and
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression
ConclusionsGLP-1RAs and SGLT2is lead to similar benefits on MACE, CVD, MI, and ACD in adults with type  2 diabetes. The benefit from SGLT2is on HHF is greater than that from GLP-1RAs, while GLP-1RAs vs. placebo significantly reduce stroke whereas SGLT2is do not. The two drug classes reduce cardiovascular events independent of reductions of systolic blood pressure and body weight. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Diabetes Therapy Podcast: ATTD Conference Highlights
(Source: Diabetes Therapy)
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People  ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
AbstractIntroductionOlder patients with type 2 diabetes (T2D) are at increased risk of diabetic nephropathy and mild renal insufficiency. This analysis compared the anti-hyperglycemic efficacy and safety of sitagliptin with dapagliflozin in patients  ≥ 65 years of age with T2D and mild renal insufficiency.MethodsThis was a post hoc analysis of data from 410 patients  ≥ 65 years old who participated in a 24-week, randomized, double-blind clinical trial (CompoSIT-R [comparison of sitagliptin with dapagliflozin in mild renal impairment]; NCT02532855) in T2D patients with mild renal ...
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study
ConclusionsSwitching to Gla-300 from first-generation basal insulin in the real world is associated with improvements in metabolic control despite a suboptimal titration of both basal and short-acting insulins. Inertia in insulin titration documented in the Gla-100 cohort is also observed with the second-generation basal insulin. The switch to Gla-300 from Deg-100 was associated with a decrease in body weight of − 1.47 kg despite a slight increase in short-acting insulin daily doses of about + 2 U. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis
ConclusionDiscontinuing ASA after short-term use for the treatment of patients with T2DM following PCI was not associated with any increased cardiovascular outcomes. Also, discontinuing ASA after short-term use and continuing the use of a P2Y12 inhibitor were somewhat safer in these patients with T2DM. Further research should follow. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial
AbstractIntroductionTo compare blood glucose variability (GV) in Chinese participants with type 2 diabetes mellitus (T2DM) whose blood glucose levels are inadequately controlled with metformin monotherapy after twice-daily exenatide or biphasic insulin aspart 30 (BIAsp30).MethodsIn this 16-week multicenter, randomized clinical trial, 104 participants were randomized 1:1 to receive exenatide (exenatide group) or BIAsp30 (BIAsp30 group) twice daily. All participants continued metformin treatment. The primary outcome was the change in GV as measured by a continuous glucose monitoring system (CGMS) from baseline to 16  we...
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
AbstractDrug therapies for people with heart failure and preserved ejection fraction (HFpEF) are often limited to diuretics to improve symptoms as no therapies demonstrate a mortality benefit in this cohort. People with diabetes have a high risk of developing HFpEF and vice versa, suggesting shared pathophysiological mechanisms exist, which in turn engenders the potential for shared treatments. Dapagliflozin is a sodium –glucose co-transporter 2 (SGLT2) inhibitor which has demonstrated significantly improved cardiovascular and hospitalisation for heart failure (HHF) outcomes in previous cardiovascular outcome tr...
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review
This article provides an up-to-date review of the study data describing the clinical profile of degludec, and aims to give helpful and practical advice to prescribers about its use. While the clinical benefits of degludec are described, it is also acknowledged that further study is required to better understand how its clinical performance compares with that of insulin glargine 300 units/mL. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 16, 2020 Category: Endocrinology Source Type: research

Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes
AbstractDiabetes is a major threat to people ’s health and has become a burden worldwide. Current drugs for diabetes have limitations, such as different drug responses among individuals, failure to achieve glycemic control, and adverse effects. Exploring more effective therapeutic strategies for patients with diabetes is crucial. Currently p harmacogenomics has provided potential for individualized drug therapy based on genetic and genomic information of patients, and has made precision medicine possible. Responses and adverse effects to antidiabetic drugs are significantly associated with gene polymorphisms in patie...
Source: Diabetes Therapy - September 14, 2020 Category: Endocrinology Source Type: research

Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data
ConclusionCREDEM-DKD is an important new tool in the evaluation of treatment interventions in the DKD population.Trial RegistrationClinicalTrials.gov identifier, NCT02065791. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 14, 2020 Category: Endocrinology Source Type: research

Continuous Lumbar Sympathetic Blockade Enhances the Effect of Lumbar Sympatholysis on Refractory Diabetic Neuropathy: A Randomized Controlled Trial
ConclusionCombined treatment with continuous lumbar sympathetic block followed by neurolysis with alcohol provided more benefit in all assessed outcomes than sympathetic alcohol neurolysis alone. The results show that the procedures were associated with satisfactory safety outcomes and sustained analgesic effects, thereby providing clinical evidence supporting the use of this novel treatment for patients with painful diabetic neuropathy. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 10, 2020 Category: Endocrinology Source Type: research

Looping with Do-It-Yourself Artificial Pancreas Systems During Ramadan Fasting in Type 1 Diabetes Mellitus: Perspectives of a User and a Physician
AbstractHybrid closed-loop automated insulin delivery systems have helped type 1 diabetes (T1D) users close the loop between glucose monitoring and insulin delivery, a very important step in efforts to simulate the glucose-responsive insulin secretory function of a healthy pancreas. Do-It-Yourself Artificial Pancreas Systems (DIY APS) are a form of hybrid closed-loop system that use open-source algorithms, which govern the delivery of insulin in response to interstitial glucose and other variables that are personalized to an individual. The flexibility and customization afforded by these systems make them amenable for use ...
Source: Diabetes Therapy - September 8, 2020 Category: Endocrinology Source Type: research

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study
This study aimed to investigate real-world effectiveness of GLP-1 RAs or BI in adults with T2D poorly controlled on oral antihyperglycemic drugs (OADs).MethodsThis was a retrospective, observational, longitudinal cohort study of adults with T2D from the US Optum Humedica ® database and UK Clinical Practice Research Datalink, who initiated either injectable between January 1, 2010, and June 30, 2016. Baseline characteristics, glycated hemoglobin (HbA1c) change, and cumulative percentage reaching HbA1c 
Source: Diabetes Therapy - September 8, 2020 Category: Endocrinology Source Type: research

Ramadan and Diabetes: A Narrative Review and Practice Update
AbstractFasting in the Islamic month of Ramadan is obligatory for all sane, healthy adult Muslims. The length of the day varies significantly in temperate regions —typically lasting ≥ 18 h during peak summer in the UK. The synodic nature of the Islamic calendar means that Ramadan migrates across all four seasons over an approximately 33-year cycle. Despite valid exemptions, there is an intense desire to fast during this month, even among those who are considered to be at high risk, including many individuals with diabetes mellitus. In this review we explore the current scientific and clin...
Source: Diabetes Therapy - September 8, 2020 Category: Endocrinology Source Type: research

Impact of Liver Cirrhosis on Incidence of Dialysis Among Patients with Type 2 Diabetes
ConclusionLiver cirrhosis is an independent risk factor for dialysis in patients with T2DM. Participating in the P4P program for diabetes care may reduce the risk of requiring dialysis in patients with T2DM. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 7, 2020 Category: Endocrinology Source Type: research

Insulin Injection Practices in a Population of Canadians with Diabetes: An Observational Study
ConclusionPatients commonly make insulin injection errors. Patient and physician education on optimal insulin injection technique continues to be an unmet medical need for the treatment of patients with diabetes. Prospective trials examining the impact of new technology, diabetes educational teams, and e-learning as educational interventions are potential avenues to explore in future studies to support improved insulin injection technique. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 6, 2020 Category: Endocrinology Source Type: research

A Prospective Longitudinal Study on the Relationship Between Glucose Fluctuation and Cognitive Function in Type 2 Diabetes: PROPOSAL Study Protocol
AbstractIntroductionAlthough the risk of dementia among patients with type 2 diabetes mellitus (T2DM) is double that of those without T2DM, the mechanism remains to be elucidated and the glycemic goal to prevent progression of cognitive impairment is unclear. Results from cross-sectional studies suggest that glucose fluctuations are associated with impairment of cognitive function among T2DM patients. Therefore, the aim of the longitudinal study described here is to evaluate the relationships between glucose fluctuation indexes assessed by continuous glucose monitoring (CGM) and cognitive function among elderly patients wi...
Source: Diabetes Therapy - September 4, 2020 Category: Endocrinology Source Type: research

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
ConclusionThe information from this varied panel of PRO instruments collected at baseline complements clinical outcomes data. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 2, 2020 Category: Endocrinology Source Type: research

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
AbstractThe growing epidemic of obesity and diabetes represents a growing health emergency, exemplified by a marked increase in cardiovascular and renal disease. As such, healthcare systems are increasingly focussing on therapeutic approaches to address these challenges. Cardiovascular outcome trials (CVOTs) evaluating glucagon-like peptide-1 (GLP-1) analogues have previously observed significant improvements in major adverse cardiac events in people with type 2 diabetes (T2D). However, their impact in obese people without T2D is unknown. The SELECT study is the first pharmacotherapy study in obesity powered for cardiovasc...
Source: Diabetes Therapy - September 2, 2020 Category: Endocrinology Source Type: research

COVID-19, Diabetes and Ramadan
(Source: Diabetes Therapy)
Source: Diabetes Therapy - September 2, 2020 Category: Endocrinology Source Type: research

Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis
AbstractIntroductionLiraglutide is a glucagon-like peptide-1 analogue used to treat type 2 diabetes mellitus (T2DM). To date, limited long-term data (>  2 years) exist comparing real-world diabetes-related effectiveness and costs for liraglutide versus insulin treatment.MethodsThis retrospective claims data analysis covered the period from 1 January 2010 to 31 December 2017 and included continuously insured patients with T2DM who initiated insulin or liraglutide and had 3.5 or 5  years’ follow-up data, identified using the German AOK PLUS dataset. Propensity score matching (PSM) was used to adjust...
Source: Diabetes Therapy - September 1, 2020 Category: Endocrinology Source Type: research

Effect of Dipeptidyl Peptidase  4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis
AbstractIntroductionTo evaluate the efficacy and safety of dipeptidyl peptidase  4 inhibitors (DPP4i) used in combination with insulin in patients with type 2 diabetes mellitus (T2DM).MethodsWe searched the MEDLINE, Embase, and Cochrane library databases for randomized controlled trials (RCTs) published through June 2018. Studies with at least a 12-week treatment period were included to compare the addition of DPP4i to insulin with insulin control therapy. Meanwhile, groups on a stable insulin dosage (insulin-stable subgroup) or titrating insulin dosage (insulin-flexible subgroup) were analyzed separately.Results...
Source: Diabetes Therapy - September 1, 2020 Category: Endocrinology Source Type: research

The Effects of Mobile-App-Based Low-Carbohydrate Dietary Guidance on Postprandial Hyperglycemia in Adults with Prediabetes
This study aims to determine if mobile-app-based low-carbohydrate dietary guidance will reduce exposure to postprandial hyperglycemia in adults with prediabetes.MethodsThis single-blind, randomized controlled pilot study included 100 participants (39 men; mean age 53.6  ± 11.9 years) and was performed in the PKU Care CNOOC Hospital, China. The intervention group (n = 57) received low-carbohydrate dietary guidance through a moblie app (CAReNA) for 3 months, while the control group (n = 43) only received health education on a diabetic diet. The primary outcome was change ...
Source: Diabetes Therapy - August 31, 2020 Category: Endocrinology Source Type: research

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog ® in Japanese Patients with Type 1 Diabetes: PRONTO-T1D Subpopulation Analysis
ConclusionsMealtime and postmeal URLi provide effective and comparable glycemic control in Japanese patients. Mealtime URLi demonstrated more effective PPG control compared to lispro.Trial RegistrationClinicalTrials.gov, NCT03214367. (Source: Diabetes Therapy)
Source: Diabetes Therapy - August 18, 2020 Category: Endocrinology Source Type: research

A Review on Semaglutide: An Oral Glucagon-Like Peptide  1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
AbstractGlucagon-like peptide  1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of action and mode of administration. This review describes the basic and clinical pharmacology of orally administered semaglutide. It highligh ts the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability. (Source: Diabetes Therapy)
Source: Diabetes Therapy - August 18, 2020 Category: Endocrinology Source Type: research